Merck & Co., Inc. reported revenue of $16.61B for the period ended 2026-06-30, +5.1% year on year. Net income was $-1.33B, a -8.0% net margin on a 73.5% gross margin. The largest revenue line is Pharmaceuticalsegment at 89% of the total. Free cash flow for the period was $4.48B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $16.61B | +5.1% |
| Gross profit | $12.21B | — |
| Operating income | $-0.43B | — |
| Net income | $-1.33B | -130.2% |
| Gross margin | 73.5% | Net margin -8.0% |
| Revenue Q/Q | +2.0% | — |
| Segment | Revenue | Share |
|---|---|---|
| Pharmaceuticalsegment | $14.76B | 88.9% |
| Animal Healthsegment | $1.77B | 10.7% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $4.39B | 26.5% |
| R&D | $9.74B | 58.7% |
| SG&A | $2.90B | 17.5% |
| Tax & other | $0.90B | 5.4% |
| Item | Amount |
|---|---|
| Total assets | $129.80B |
| Total liabilities | $87.82B |
| Shareholders' equity | $41.98B |
| Equity / assets | 32.3% |
| Operating cash flow | $5.37B |
| Capital expenditure | $0.89B |
| Free cash flow | $4.48B |
| Cash conversion (OCF / net income) | -402% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
META ・ MET ・ MTD ・ MGM ・ MCHP ・ MU ・ MSFT ・ MAA ・ MRNA ・ TAP ・ MDLZ ・ MPWR
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies